Search
Search Results
-
Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application
Nonalcoholic steatohepatitis (NASH) is a widely prevalent disease, but approved pharmaceutical treatments are not available. As such, there is great...
-
Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
BackgroundNon-alcoholic liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and it can progress to non-alcoholic...
-
NAFLD and NASH: The Metabolically Diseased Liver
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease, with a global prevalence of approximately 24% in the general...
-
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) occurs due to the accumulation of fat in the liver, leading to fatal liver diseases such as nonalcoholic...
-
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
PurposeNon-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver disease, affecting 30% of the global population. NAFLD...
-
MicroRNA regulation of AMPK in nonalcoholic fatty liver disease
Obesity-associated nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is the leading cause of liver failure and...
-
A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD). Obesity is a known risk factor of NASH, which, in...
-
Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease worldwide, consisting of a broad spectrum of diseases such as simple...
-
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis (NASH), defined by the presence of NASH, high histological...
-
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review
Liver cirrhosis due to nonalcoholic steatohepatitis (NASH) is a life-threatening condition with increasing incidence world-wide. Although its...
-
Liver saturated fat content associates with hepatic DNA methylation in obese individuals
BackgroundAccumulation of saturated fatty acids (SFAs) in the liver is known to induce hepatic steatosis and inflammation causing non-alcoholic fatty...
-
Recent updates on targeting the molecular mediators of NAFLD
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common disease worldwide in an era of rapid economic growth. NAFLD is a...
-
Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition with a complex etiology. Its incidence is increasing globally in parallel...
-
Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
BackgroundThere are emerging studies suggesting that non-alcoholic fatty liver disease (NAFLD) is a heterogeneous disease with multiple etiologies...
-
Role of Renin-Angiotensin System in the Pathogenesis and Progression of Non-alcoholic Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases and is increasing simultaneously with obesity and Type 2...
-
Challenges and opportunities in NASH drug development
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represent a growing worldwide epidemic and a...
-
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool
BackgroundNon-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease worldwide, being non-alcoholic steatohepatitis...
-
Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
Background and ObjectivesNon-alcoholic fatty liver disease (NAFLD) is a progressive liver disorder and is usually accompanied by obesity, metabolic...
-
Modulation of hepatic stellate cells by Mutaflor® probiotic in non-alcoholic fatty liver disease management
BackgroundNAFLD and NASH are emerging as primary causes of chronic liver disease, indicating a need for an effective treatment. Mutaflor® probiotic,...
-
The Role of Senescence in NASH-Related HCC
Nonalcoholic fatty liver disease (NAFLD) has emerged as the predominant cause of chronic liver injury worldwide, mainly due to the epidemic spread of...